董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John A. Scarlett | 男 | President, Chief Executive Officer and Chairman of the Board | 69 | 187.62万美元 | 未持股 | 2021-03-01 |
| Dawn C. Bir | 女 | Director | 50 | 12.92万美元 | 未持股 | 2021-03-01 |
| Elizabeth G. O'Farrell | 女 | Director | 56 | 13.67万美元 | 未持股 | 2021-03-01 |
| Karin Eastham | 女 | Director | 71 | 18.17万美元 | 未持股 | 2021-03-01 |
| Robert J. Spiegel | 男 | Director | 71 | 13.92万美元 | 未持股 | 2021-03-01 |
| V. Bryan Lawlis | 男 | Director | 69 | 14.42万美元 | 未持股 | 2021-03-01 |
| Susan M. Molineaux | 女 | Director | 67 | 13.42万美元 | 未持股 | 2021-03-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John A. Scarlett | 男 | President, Chief Executive Officer and Chairman of the Board | 69 | 187.62万美元 | 未持股 | 2021-03-01 |
| Anil Kapur | 男 | Executive Vice President, Corporate Strategy and Chief Commercial | 51 | 未披露 | 未持股 | 2021-03-01 |
| Aleksandra Rizo | 女 | Executive Vice President, Chief Medical Officer | 46 | 113.49万美元 | 未持股 | 2021-03-01 |
| Melissa A. Kelly Behrs | 女 | Executive Vice President, Chief Business Officer | 57 | 100.75万美元 | 未持股 | 2021-03-01 |
| Stephen N. Rosenfield | 男 | Executive Vice President, Chief Legal Officer and Corporate Secretary | 71 | 87.87万美元 | 未持股 | 2021-03-01 |
| Olivia K. Bloom | 女 | Executive Vice President, Finance, Chief Financial Officer | 52 | 100.42万美元 | 未持股 | 2021-03-01 |
| Andrew J. Grethlein | 男 | Executive Vice President, Chief Operating Officer | 56 | 103.42万美元 | 未持股 | 2021-03-01 |
董事简历
中英对照 | 中文 | 英文- John A. Scarlett
-
John A. Scarlett，2011年9月，担任我们首席执行官和董事，2012年1月以来担任总裁。在加入Geron之前，2009年2月以来，Scarlett博士是一家肿瘤学为主导方向的私营生物制药公司Proteolix的总裁，首席执行官和董事会成员，直到它2009年11月被一家肿瘤学为主导方向生物制药公司Onyx Pharmaceuticals收购。2002年2月以来，Scarlett博士担任一家内分泌学为主导方向的生物制药公司Tercica的首席执行官和董事会成员，之后它后来被Ipsen, S.A.收购，也从2002年2月到2007年2月担任它的总裁。1993年3月至2001年5月，Scarlett博士担任Sensus Drug Development Corporation的总裁兼首席执行官。1995年，他联合创立了一家合法生物制药制造公司Covance Biotechnology Services，并从它成立以来到2000年，担任它的董事会成员。1991年到1993年，Scarlett博士领导北美临产研究中心，担任一家Novo Nordisk A/S全资所有的子公司Novo Nordisk Pharmaceuticals的医疗科学事务官。Scarlett博士拥有厄勒姆学院化学专业学士学位和芝加哥大学普利兹克医学院的医学博士学位。
John A. Scarlett has served as Geron Corporation Chairman of the Board since December 2018 Geron Corporation Chief Executive Officer and a director since joining Geron in September 2011 and President since January 2012. Dr. Scarlett also serves as a member of the boards of directors for Chiasma, Inc., a biopharmaceutical company focused on transforming injectable drugs into oral medications, since February 2015 and CytomX Therapeutics, Inc., an oncology-oriented company, since June 2016. Prior to joining Geron, Dr. Scarlett served as President, Chief Executive Officer and a member of the board of directors of Proteolix, Inc., a privately-held, oncology-oriented biopharmaceutical company, from February 2009 until its acquisition by Onyx Pharmaceuticals, Inc., an oncology-oriented biopharmaceutical company, in November 2009. From February 2002 until its acquisition by Ipsen, S.A. in October 2008 Dr. Scarlett served as the Chief Executive Officer and a member of the board of directors of Tercica, Inc., an endocrinology-oriented biopharmaceutical company, and also as its President from February 2002 through February 2007. From March 1993 to May 2001 Dr. Scarlett served as President and Chief Executive Officer of Sensus Drug Development Corporation, a privately-held company focused on endocrine disorders. In 1995 he co-founded Covance Biotechnology Services, Inc., a contract biopharmaceutical manufacturing operation, and served as a member of its board of directors from inception to 2000. From 1991 to 1993 Dr. Scarlett headed the North American Clinical Development Center and served as Senior Vice President of Medical and Scientific Affairs at Novo Nordisk Pharmaceuticals, Inc., a wholly-owned subsidiary of Novo Nordisk A/S, a global pharmaceutical company. Dr. Scarlett received his B.A. degree in chemistry from Earlham College and his M.D. from the University of Chicago, Pritzker School of Medicine. - John A. Scarlett，2011年9月，担任我们首席执行官和董事，2012年1月以来担任总裁。在加入Geron之前，2009年2月以来，Scarlett博士是一家肿瘤学为主导方向的私营生物制药公司Proteolix的总裁，首席执行官和董事会成员，直到它2009年11月被一家肿瘤学为主导方向生物制药公司Onyx Pharmaceuticals收购。2002年2月以来，Scarlett博士担任一家内分泌学为主导方向的生物制药公司Tercica的首席执行官和董事会成员，之后它后来被Ipsen, S.A.收购，也从2002年2月到2007年2月担任它的总裁。1993年3月至2001年5月，Scarlett博士担任Sensus Drug Development Corporation的总裁兼首席执行官。1995年，他联合创立了一家合法生物制药制造公司Covance Biotechnology Services，并从它成立以来到2000年，担任它的董事会成员。1991年到1993年，Scarlett博士领导北美临产研究中心，担任一家Novo Nordisk A/S全资所有的子公司Novo Nordisk Pharmaceuticals的医疗科学事务官。Scarlett博士拥有厄勒姆学院化学专业学士学位和芝加哥大学普利兹克医学院的医学博士学位。
- John A. Scarlett has served as Geron Corporation Chairman of the Board since December 2018 Geron Corporation Chief Executive Officer and a director since joining Geron in September 2011 and President since January 2012. Dr. Scarlett also serves as a member of the boards of directors for Chiasma, Inc., a biopharmaceutical company focused on transforming injectable drugs into oral medications, since February 2015 and CytomX Therapeutics, Inc., an oncology-oriented company, since June 2016. Prior to joining Geron, Dr. Scarlett served as President, Chief Executive Officer and a member of the board of directors of Proteolix, Inc., a privately-held, oncology-oriented biopharmaceutical company, from February 2009 until its acquisition by Onyx Pharmaceuticals, Inc., an oncology-oriented biopharmaceutical company, in November 2009. From February 2002 until its acquisition by Ipsen, S.A. in October 2008 Dr. Scarlett served as the Chief Executive Officer and a member of the board of directors of Tercica, Inc., an endocrinology-oriented biopharmaceutical company, and also as its President from February 2002 through February 2007. From March 1993 to May 2001 Dr. Scarlett served as President and Chief Executive Officer of Sensus Drug Development Corporation, a privately-held company focused on endocrine disorders. In 1995 he co-founded Covance Biotechnology Services, Inc., a contract biopharmaceutical manufacturing operation, and served as a member of its board of directors from inception to 2000. From 1991 to 1993 Dr. Scarlett headed the North American Clinical Development Center and served as Senior Vice President of Medical and Scientific Affairs at Novo Nordisk Pharmaceuticals, Inc., a wholly-owned subsidiary of Novo Nordisk A/S, a global pharmaceutical company. Dr. Scarlett received his B.A. degree in chemistry from Earlham College and his M.D. from the University of Chicago, Pritzker School of Medicine.
- Dawn C. Bir
-
Dawn C. Bir，自2019年3月起担任Geron的董事。自2016年9月起，她担任Reata Pharmaceuticals, Inc.（一家生物制药公司）的首席商务官，在那里她领导营销、市场准入、销售和商业运营。从2013年2月到2016年9月，Bir女士担任Pharmacyclics LLC （AbbVie公司）的销售副总裁，在那里她建立并领导他们的第一个血液学全国销售组织，并负责IMBRUVICA在美国和波多黎各的推出。女士从2011年10月到2013年2月Bir担任销售和营销的副总裁天空制药包装有限公司& Rx Pak，单位在美国制药McKesson分工和专业解决方案公司，全球医疗保健公司，在那里她负责两家公司和收入中心，并领导多个职能，包括销售、市场营销、合同管理、项目管理和客户服务。从1996年到2011年10月，她担任Genentech, Inc.（罗氏集团（全球制药公司）的成员）和Bristol-Myers Squibb company（全球制药公司）的几个商业和销售职位，并不断被提拔。她持有宾厄姆顿大学（Binghamton University）生物学学士学位。
Dawn C. Bir has served as a director of Geron since March 2019. Since September 2016 Ms. Bir has served as the Chief Commercial Officer of Reata Pharmaceuticals, Inc., a biopharmaceutical company, where she leads marketing, market access, sales, and commercial operations. From February 2013 to September 2016 Ms. Bir served as Vice President of Sales with Pharmacyclics LLC, an AbbVie company, where she built and led their first hematology national sales organization, and was responsible for the launch of IMBRUVICA in the United States and Puerto Rico. From October 2011 to February 2013 Ms. Bir served as Vice President of Sales & Marketing of SKY Pharmaceuticals Packaging, Inc. & Rx Pak, a unit within the U.S. pharmaceutical and specialty solutions division of McKesson Corporation, a global healthcare company, where she was responsible for two companies and revenue centers, and led multiple functions, including sales, marketing, contract management, project management and customer service. From 1996 to October 2011 Ms. Bir held several commercial and sales positions of increasing responsibility within Genentech, Inc., a member of the Roche Group, a global pharmaceutical company, and Bristol-Myers Squibb Company, a global pharmaceutical company. Ms. Bir holds a B.S. in Biology from Binghamton University. - Dawn C. Bir，自2019年3月起担任Geron的董事。自2016年9月起，她担任Reata Pharmaceuticals, Inc.（一家生物制药公司）的首席商务官，在那里她领导营销、市场准入、销售和商业运营。从2013年2月到2016年9月，Bir女士担任Pharmacyclics LLC （AbbVie公司）的销售副总裁，在那里她建立并领导他们的第一个血液学全国销售组织，并负责IMBRUVICA在美国和波多黎各的推出。女士从2011年10月到2013年2月Bir担任销售和营销的副总裁天空制药包装有限公司& Rx Pak，单位在美国制药McKesson分工和专业解决方案公司，全球医疗保健公司，在那里她负责两家公司和收入中心，并领导多个职能，包括销售、市场营销、合同管理、项目管理和客户服务。从1996年到2011年10月，她担任Genentech, Inc.（罗氏集团（全球制药公司）的成员）和Bristol-Myers Squibb company（全球制药公司）的几个商业和销售职位，并不断被提拔。她持有宾厄姆顿大学（Binghamton University）生物学学士学位。
- Dawn C. Bir has served as a director of Geron since March 2019. Since September 2016 Ms. Bir has served as the Chief Commercial Officer of Reata Pharmaceuticals, Inc., a biopharmaceutical company, where she leads marketing, market access, sales, and commercial operations. From February 2013 to September 2016 Ms. Bir served as Vice President of Sales with Pharmacyclics LLC, an AbbVie company, where she built and led their first hematology national sales organization, and was responsible for the launch of IMBRUVICA in the United States and Puerto Rico. From October 2011 to February 2013 Ms. Bir served as Vice President of Sales & Marketing of SKY Pharmaceuticals Packaging, Inc. & Rx Pak, a unit within the U.S. pharmaceutical and specialty solutions division of McKesson Corporation, a global healthcare company, where she was responsible for two companies and revenue centers, and led multiple functions, including sales, marketing, contract management, project management and customer service. From 1996 to October 2011 Ms. Bir held several commercial and sales positions of increasing responsibility within Genentech, Inc., a member of the Roche Group, a global pharmaceutical company, and Bristol-Myers Squibb Company, a global pharmaceutical company. Ms. Bir holds a B.S. in Biology from Binghamton University.
- Elizabeth G. O'Farrell
-
Elizabeth G. O'Farrell自2019年3月起担任Geron董事。Farrell女士自2020年12月起担任Inhibikase Therapeutics（一家创新小分子激酶抑制剂疗法以治疗神经感染和神经退行性疾病的制药公司）和LENSAR，Inc.（一家全球医疗技术公司）董事会成员，自2021年1月起。2017年12月，Farrell女士从礼来公司（Eli Lilly and Company）离开。礼来公司是一家全球性制药公司，在礼来公司担任了24年的职业生涯，她曾担任财务和公司治理方面的多个高级管理职位，最近一次担任首席采购官和全球共享服务主管，任期为2012年1月至2017年12月份。在此之前，她还担任政策和财务高级副总裁；财务高级副总裁；礼来美国首席财务官；礼来加拿大公司首席财务官；和总审计师。在加入礼来之前，Farrell女士是Boise Cascade Office Products的会计师，并在专业会计师事务所Whipple&Company和国际公共会计师事务所Price Waterhouse担任审计师。Farrell女士拥有印第安纳大学荣誉会计学士学位和管理信息系统硕士学位。
Elizabeth G. O'Farrell has served as a director of Geron since March 2019. Ms. O'Farrell also serves as a member of the board of directors of Inhibikase Therapeutics, a pharmaceutical company innovating small-molecule kinase inhibitor therapeutics for treatment of neurological infections and neurodegenerative diseases, since December 2020 and LENSAR, Inc., a global medical technology company, since January 2021. In December 2017 Ms. O'Farrell retired from a 24-year career with Eli Lilly and Company, a global pharmaceutical company, where she held several senior management positions in finance and corporate governance, most recently serving as Chief Procurement Officer and Head of Global Shared Services from January 2012 to December 2017. Prior to that position, she also served as Senior Vice President, Policy and Finance; Senior Vice President, Finance; Chief Financial Officer, Lilly USA; Chief Financial Officer, Lilly Canada; and General Auditor. Before joining Eli Lilly, Ms. O'Farrell was an accountant with Boise Cascade Office Products, and served as an auditor at Whipple & Company, a professional accountancy firm, and Price Waterhouse, an international public accounting firm. Ms. O'Farrell holds a B.S. in accounting with honors and an M.B.A. in management information systems, both from Indiana University. - Elizabeth G. O'Farrell自2019年3月起担任Geron董事。Farrell女士自2020年12月起担任Inhibikase Therapeutics（一家创新小分子激酶抑制剂疗法以治疗神经感染和神经退行性疾病的制药公司）和LENSAR，Inc.（一家全球医疗技术公司）董事会成员，自2021年1月起。2017年12月，Farrell女士从礼来公司（Eli Lilly and Company）离开。礼来公司是一家全球性制药公司，在礼来公司担任了24年的职业生涯，她曾担任财务和公司治理方面的多个高级管理职位，最近一次担任首席采购官和全球共享服务主管，任期为2012年1月至2017年12月份。在此之前，她还担任政策和财务高级副总裁；财务高级副总裁；礼来美国首席财务官；礼来加拿大公司首席财务官；和总审计师。在加入礼来之前，Farrell女士是Boise Cascade Office Products的会计师，并在专业会计师事务所Whipple&Company和国际公共会计师事务所Price Waterhouse担任审计师。Farrell女士拥有印第安纳大学荣誉会计学士学位和管理信息系统硕士学位。
- Elizabeth G. O'Farrell has served as a director of Geron since March 2019. Ms. O'Farrell also serves as a member of the board of directors of Inhibikase Therapeutics, a pharmaceutical company innovating small-molecule kinase inhibitor therapeutics for treatment of neurological infections and neurodegenerative diseases, since December 2020 and LENSAR, Inc., a global medical technology company, since January 2021. In December 2017 Ms. O'Farrell retired from a 24-year career with Eli Lilly and Company, a global pharmaceutical company, where she held several senior management positions in finance and corporate governance, most recently serving as Chief Procurement Officer and Head of Global Shared Services from January 2012 to December 2017. Prior to that position, she also served as Senior Vice President, Policy and Finance; Senior Vice President, Finance; Chief Financial Officer, Lilly USA; Chief Financial Officer, Lilly Canada; and General Auditor. Before joining Eli Lilly, Ms. O'Farrell was an accountant with Boise Cascade Office Products, and served as an auditor at Whipple & Company, a professional accountancy firm, and Price Waterhouse, an international public accounting firm. Ms. O'Farrell holds a B.S. in accounting with honors and an M.B.A. in management information systems, both from Indiana University.
- Karin Eastham
-
Karin Eastham，自2019年9月起担任Personalis, Inc.的董事。她于2018年9月被任命为Personalis, Inc.董事会成员。Eastham女士目前任职于几家生命科学公司的董事会。2009年3月以来担任Geron董事。Eastham女士也担任一家法兰克福证券交易所上市的生物技术公司MorphoSys AG，一家生命科学工具和试剂制造商Illumina，以及一家私营分子诊断公司Veracyte的董事。Eastham女士过去5年，2009年以来，也担任一家生物制药公司Trius Therapeutics的董事，直到它2013年被卖出；2005年以来，担任一家生物制药公司Amylin Pharmaceuticals的董事，直到它2012年被卖出；2008年以来，担任一家专业实验服务提供商Genoptix的董事，直到它2011年被卖出；2003年以来，担任一家生物制药公司Tercica的董事，直到它2008年被卖出；2005年以来，担任一家生物制药公司SGX Pharmaceuticals的董事，直到它2008年被卖出。2004年5月到2008年9月，她担任一家涉及基础生物医疗项目的非盈利公司伯纳姆医学研究所的执行副总裁，首席运营官和董事会成员。1999年到2004年，Eastham女士担任一家生物技术公司Diversa Corporation的金融高级副总裁，首席财务官和秘书长。她之前在一家计算化学公司CombiChem和一家生物制药公司Cytel Corporation担任相似的职位。1976年到1988年，Eastham女士也在一家生物制药公司Boehringer Mannheim Corporation担任几个职位，包括金融副总裁。Eastham女士拥有印第安纳大学的学士学位和MBA学位，她是一名注册会计师。
Karin Eastham, has served on Personalis, Inc. of Directors since September 2019. She was appointed to serve as a member of our board of directors in September 2018. Ms. Eastham currently serves on the boards of directors of several life sciences companies. Ms. Eastham has served on the board of directors of Geron Corporation since March 2009 Veracyte, Inc. since December 2012 and Personalis, Inc. since November 2019. Ms. Eastham served as a member of the board of directors of Illumina Inc. from August 2004 to May 2019 MorphoSys AG from May 2012 to May 2017 Amylin Pharmaceuticals, Inc. from September 2005 until its acquisition in August 2012 Genoptix, Inc. from July 2008 until its acquisition in March 2011 Tercica, Inc. from December 2003 until its acquisition in October 2008 and Trius Therapeutics, Inc. from February 2007 until its acquisition in September 2013. From May 2004 to September 2008 Ms. Eastham served as Executive Vice President and Chief Operating Officer, and as a member of the Board of Trustees, of the Burnham Institute for Medical Research now Sanford Burnham Prebys Medical Discovery Institute, a non-profit corporation engaged in biomedical research. From April 1999 to May 2004 Ms. Eastham served as Senior Vice President, Chief Financial Officer and Secretary of Diversa Corporation, a biotechnology company. Ms. Eastham previously held similar positions with CombiChem, Inc., a computational chemistry company, and Cytel Corporation, a biopharmaceutical company. Ms. Eastham also held several positions, including Vice President, Finance, at Boehringer Mannheim Diagnostics, from 1976 to 1988. Ms. Eastham received a B.S. in Accounting and an M.B.A. from Indiana University and is a Certified Public Accountant. - Karin Eastham，自2019年9月起担任Personalis, Inc.的董事。她于2018年9月被任命为Personalis, Inc.董事会成员。Eastham女士目前任职于几家生命科学公司的董事会。2009年3月以来担任Geron董事。Eastham女士也担任一家法兰克福证券交易所上市的生物技术公司MorphoSys AG，一家生命科学工具和试剂制造商Illumina，以及一家私营分子诊断公司Veracyte的董事。Eastham女士过去5年，2009年以来，也担任一家生物制药公司Trius Therapeutics的董事，直到它2013年被卖出；2005年以来，担任一家生物制药公司Amylin Pharmaceuticals的董事，直到它2012年被卖出；2008年以来，担任一家专业实验服务提供商Genoptix的董事，直到它2011年被卖出；2003年以来，担任一家生物制药公司Tercica的董事，直到它2008年被卖出；2005年以来，担任一家生物制药公司SGX Pharmaceuticals的董事，直到它2008年被卖出。2004年5月到2008年9月，她担任一家涉及基础生物医疗项目的非盈利公司伯纳姆医学研究所的执行副总裁，首席运营官和董事会成员。1999年到2004年，Eastham女士担任一家生物技术公司Diversa Corporation的金融高级副总裁，首席财务官和秘书长。她之前在一家计算化学公司CombiChem和一家生物制药公司Cytel Corporation担任相似的职位。1976年到1988年，Eastham女士也在一家生物制药公司Boehringer Mannheim Corporation担任几个职位，包括金融副总裁。Eastham女士拥有印第安纳大学的学士学位和MBA学位，她是一名注册会计师。
- Karin Eastham, has served on Personalis, Inc. of Directors since September 2019. She was appointed to serve as a member of our board of directors in September 2018. Ms. Eastham currently serves on the boards of directors of several life sciences companies. Ms. Eastham has served on the board of directors of Geron Corporation since March 2009 Veracyte, Inc. since December 2012 and Personalis, Inc. since November 2019. Ms. Eastham served as a member of the board of directors of Illumina Inc. from August 2004 to May 2019 MorphoSys AG from May 2012 to May 2017 Amylin Pharmaceuticals, Inc. from September 2005 until its acquisition in August 2012 Genoptix, Inc. from July 2008 until its acquisition in March 2011 Tercica, Inc. from December 2003 until its acquisition in October 2008 and Trius Therapeutics, Inc. from February 2007 until its acquisition in September 2013. From May 2004 to September 2008 Ms. Eastham served as Executive Vice President and Chief Operating Officer, and as a member of the Board of Trustees, of the Burnham Institute for Medical Research now Sanford Burnham Prebys Medical Discovery Institute, a non-profit corporation engaged in biomedical research. From April 1999 to May 2004 Ms. Eastham served as Senior Vice President, Chief Financial Officer and Secretary of Diversa Corporation, a biotechnology company. Ms. Eastham previously held similar positions with CombiChem, Inc., a computational chemistry company, and Cytel Corporation, a biopharmaceutical company. Ms. Eastham also held several positions, including Vice President, Finance, at Boehringer Mannheim Diagnostics, from 1976 to 1988. Ms. Eastham received a B.S. in Accounting and an M.B.A. from Indiana University and is a Certified Public Accountant.
- Robert J. Spiegel
-
Robert J. Spiegel于2015年1月成为Sucampo的董事。他是Spiegel Consulting，LLC的总裁兼创始人，自2012年以来一直担任威尔康奈尔医学中心的副教授。 Spiegel博士此前曾于2014年1月至2016年4月担任PTC Therapeutics，Inc.的首席医学官，并于1998年至2009年担任先灵-雅研究所的首席医学官，在1983年加入该公司后，他担任越来越重要的职务。目前担任私人生物技术公司NexImmune，Inc.和Vidac Pharma的董事长。他还自2013年8月起担任Edge Therapeutics，Inc.上市公司的董事会成员，自2010年5月起担任Geron Corporation的董事会成员，并担任许多生物技术公司的顾问。他还担任以色列生物技术基金和全球私募股权投资机构Warburg Pincus的顾问。他曾于2010年5月至2012年1月担任公开上市的生物技术公司Capstone Therapeutics Corp.的董事会成员，并于2010年7月担任公开上市的生物制药公司Talon Therapeutics的董事会成员，直到2013年7月被Spectrum Pharmaceuticals收购为止。收到他的学士学位在耶鲁大学获得博士学位，在宾夕法尼亚大学获得博士学位。
Robert J. Spiegel has served as a director of Geron since May 2010. Dr. Spiegel currently serves as an Associate Professor at the Weill Cornell Medical School, a Senior Advisor to Warburg Pincus, a private equity firm, and an Advisor to the Israel Biotech Fund, a venture investment fund. He is also a member of the board of directors of Ayala Pharmaceuticals, a clinical-stage oncology company, since December 2017; Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing targeted medicines for cancer and other proliferative diseases, since September 2018; Athenex, Inc., a global biopharmaceutical oncology company, since August 2020; and several privately-held biotechnology companies. He previously served as a director for Avior Computing Corporation, a privately-held governance risk and compliance process technology company, from October 2011 to November 2017; Talon Therapeutics, Inc., a biopharmaceutical company, from July 2010 to July 2013; Capstone Therapeutics Corp., a biotechnology company, from May 2010 to January 2012; Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, from January 2015 to January 2018; and PDS Biotechnology Corporation formerly Edge Therapeutics, Inc., a biotechnology company, from August 2013 to March 2019; the Cancer Institute of New Jersey from 1999 to 2009; and Cancer Care New Jersey from 1995 to 2011. From March 2011 to April 2016 Dr. Spiegel served as Chief Medical Officer of PTC Therapeutics, Inc., a biopharmaceutical company focused on discovering and developing treatments for rare disorders. In 2009 after 26 years with the Schering-Plough Corporation (now Merck & Co.), a global healthcare company, Dr. Spiegel retired as Chief Medical Officer and Senior Vice President of the Schering-Plough Research Institute, the pharmaceutical research arm of the Schering-Plough Corporation. His career at Schering-Plough involved various positions, including Director of clinical research for oncology, Vice President of clinical research, and Senior Vice President of worldwide clinical research. Following a residency in internal medicine, Dr. Spiegel completed a fellowship in medical oncology at the National Cancer Institute, and from 1981 to 1999 he held academic positions at the National Cancer Institute and New York University Cancer Center. Dr. Spiegel holds a B.A. from Yale University and an M.D. from the University of Pennsylvania. - Robert J. Spiegel于2015年1月成为Sucampo的董事。他是Spiegel Consulting，LLC的总裁兼创始人，自2012年以来一直担任威尔康奈尔医学中心的副教授。 Spiegel博士此前曾于2014年1月至2016年4月担任PTC Therapeutics，Inc.的首席医学官，并于1998年至2009年担任先灵-雅研究所的首席医学官，在1983年加入该公司后，他担任越来越重要的职务。目前担任私人生物技术公司NexImmune，Inc.和Vidac Pharma的董事长。他还自2013年8月起担任Edge Therapeutics，Inc.上市公司的董事会成员，自2010年5月起担任Geron Corporation的董事会成员，并担任许多生物技术公司的顾问。他还担任以色列生物技术基金和全球私募股权投资机构Warburg Pincus的顾问。他曾于2010年5月至2012年1月担任公开上市的生物技术公司Capstone Therapeutics Corp.的董事会成员，并于2010年7月担任公开上市的生物制药公司Talon Therapeutics的董事会成员，直到2013年7月被Spectrum Pharmaceuticals收购为止。收到他的学士学位在耶鲁大学获得博士学位，在宾夕法尼亚大学获得博士学位。
- Robert J. Spiegel has served as a director of Geron since May 2010. Dr. Spiegel currently serves as an Associate Professor at the Weill Cornell Medical School, a Senior Advisor to Warburg Pincus, a private equity firm, and an Advisor to the Israel Biotech Fund, a venture investment fund. He is also a member of the board of directors of Ayala Pharmaceuticals, a clinical-stage oncology company, since December 2017; Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing targeted medicines for cancer and other proliferative diseases, since September 2018; Athenex, Inc., a global biopharmaceutical oncology company, since August 2020; and several privately-held biotechnology companies. He previously served as a director for Avior Computing Corporation, a privately-held governance risk and compliance process technology company, from October 2011 to November 2017; Talon Therapeutics, Inc., a biopharmaceutical company, from July 2010 to July 2013; Capstone Therapeutics Corp., a biotechnology company, from May 2010 to January 2012; Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, from January 2015 to January 2018; and PDS Biotechnology Corporation formerly Edge Therapeutics, Inc., a biotechnology company, from August 2013 to March 2019; the Cancer Institute of New Jersey from 1999 to 2009; and Cancer Care New Jersey from 1995 to 2011. From March 2011 to April 2016 Dr. Spiegel served as Chief Medical Officer of PTC Therapeutics, Inc., a biopharmaceutical company focused on discovering and developing treatments for rare disorders. In 2009 after 26 years with the Schering-Plough Corporation (now Merck & Co.), a global healthcare company, Dr. Spiegel retired as Chief Medical Officer and Senior Vice President of the Schering-Plough Research Institute, the pharmaceutical research arm of the Schering-Plough Corporation. His career at Schering-Plough involved various positions, including Director of clinical research for oncology, Vice President of clinical research, and Senior Vice President of worldwide clinical research. Following a residency in internal medicine, Dr. Spiegel completed a fellowship in medical oncology at the National Cancer Institute, and from 1981 to 1999 he held academic positions at the National Cancer Institute and New York University Cancer Center. Dr. Spiegel holds a B.A. from Yale University and an M.D. from the University of Pennsylvania.
- V. Bryan Lawlis
-
V. Bryan Lawlis，2012年以来，他担任Geron董事。他目前担任一家专门从事罕见遗传病生物制药公司BioMarin Pharmaceuticals，一家专门从事治疗人类疾病定制抗体的生物制药公司KaloBios Pharmaceuticals和几个私营生物技术公司的董事。Lawlis博士是一家处于早期阶段，由他2006年联合建立私营生物技术公司Itero Biopharmaceuticals的总裁兼首席执行官。Lawlis 博士2004年8月起曾担任一家专注于药物投递技术的专门药品公司Aradigm Corporation的总裁兼首席执行官，也是2005年2月以来，担任它的董事会成员，这两个职位都一直担任到2006年8月。Lawlis博士2003年6月到2004年8月担任Aradigm Corporation的总裁兼首席运营官，2001年11月到2003年6月担任它的首席运营官。之前，Lawlis博士联合创立了一家合法生物制药制造公司Covance Biotechnology Services，并且1996年到1999年担任它的总裁兼首席执行官，1999年到2001年担任董事长，之后2001年它被卖给Akzo Nobel, NV的子公司Diosynth RTP。1981年到1996年，Lawlis博士受雇于Genencor和Genentech。他在Genentech的最后职位是工艺流程科学副总裁。Lawlis博士拥有得克萨斯大学奥斯汀分校微生物学专业学士学位，以及华盛顿州立大学生物化学专业博士学位。
V. Bryan Lawlis has served as a director of Geron since March 2012. He also serves as a member of the boards of directors of BioMarin Pharmaceutical, Inc., a biopharmaceutical company specializing in rare genetic diseases, since June 2007; Coherus BioSciences, Inc., a biologics platform company specializing in biosimilars, since May 2014; Aeglea BioTherapeutics, Inc., a biotechnology company specializing in human enzyme therapeutics for rare genetic diseases and cancer, since July 2018; and several privately-held biotechnology companies. In addition, he serves as an advisor to Phoenix Venture Partners, a venture capital firm specializing in manufacturing technologies, since October 2015. Dr. Lawlis previously served as a director of KaloBios Pharmaceuticals, Inc., a biopharmaceutical company, from August 2013 to September 2014; and Sutro Biopharma, Inc., a biologics platform company specializing in therapeutics for cancer and autoimmune disorders, from January 2004 to June 2019. Dr. Lawlis was the President and Chief Executive Officer of Itero Biopharmaceuticals LLC, a privately-held, early stage biopharmaceutical company that he co-founded, from 2006 to 2011. Dr. Lawlis also held several senior management positions in the biopharmaceutical industry, including President and Chief Executive Officer of Aradigm Corporation, a specialty drug company focused on drug delivery technologies, and President and Chief Executive Officer of Covance Biotechnology Services, a contract biopharmaceutical manufacturing operation, which he co-founded. Dr. Lawlis holds a B.A. in microbiology from the University of Texas at Austin and a Ph.D. in biochemistry from Washington State University. - V. Bryan Lawlis，2012年以来，他担任Geron董事。他目前担任一家专门从事罕见遗传病生物制药公司BioMarin Pharmaceuticals，一家专门从事治疗人类疾病定制抗体的生物制药公司KaloBios Pharmaceuticals和几个私营生物技术公司的董事。Lawlis博士是一家处于早期阶段，由他2006年联合建立私营生物技术公司Itero Biopharmaceuticals的总裁兼首席执行官。Lawlis 博士2004年8月起曾担任一家专注于药物投递技术的专门药品公司Aradigm Corporation的总裁兼首席执行官，也是2005年2月以来，担任它的董事会成员，这两个职位都一直担任到2006年8月。Lawlis博士2003年6月到2004年8月担任Aradigm Corporation的总裁兼首席运营官，2001年11月到2003年6月担任它的首席运营官。之前，Lawlis博士联合创立了一家合法生物制药制造公司Covance Biotechnology Services，并且1996年到1999年担任它的总裁兼首席执行官，1999年到2001年担任董事长，之后2001年它被卖给Akzo Nobel, NV的子公司Diosynth RTP。1981年到1996年，Lawlis博士受雇于Genencor和Genentech。他在Genentech的最后职位是工艺流程科学副总裁。Lawlis博士拥有得克萨斯大学奥斯汀分校微生物学专业学士学位，以及华盛顿州立大学生物化学专业博士学位。
- V. Bryan Lawlis has served as a director of Geron since March 2012. He also serves as a member of the boards of directors of BioMarin Pharmaceutical, Inc., a biopharmaceutical company specializing in rare genetic diseases, since June 2007; Coherus BioSciences, Inc., a biologics platform company specializing in biosimilars, since May 2014; Aeglea BioTherapeutics, Inc., a biotechnology company specializing in human enzyme therapeutics for rare genetic diseases and cancer, since July 2018; and several privately-held biotechnology companies. In addition, he serves as an advisor to Phoenix Venture Partners, a venture capital firm specializing in manufacturing technologies, since October 2015. Dr. Lawlis previously served as a director of KaloBios Pharmaceuticals, Inc., a biopharmaceutical company, from August 2013 to September 2014; and Sutro Biopharma, Inc., a biologics platform company specializing in therapeutics for cancer and autoimmune disorders, from January 2004 to June 2019. Dr. Lawlis was the President and Chief Executive Officer of Itero Biopharmaceuticals LLC, a privately-held, early stage biopharmaceutical company that he co-founded, from 2006 to 2011. Dr. Lawlis also held several senior management positions in the biopharmaceutical industry, including President and Chief Executive Officer of Aradigm Corporation, a specialty drug company focused on drug delivery technologies, and President and Chief Executive Officer of Covance Biotechnology Services, a contract biopharmaceutical manufacturing operation, which he co-founded. Dr. Lawlis holds a B.A. in microbiology from the University of Texas at Austin and a Ph.D. in biochemistry from Washington State University.
- Susan M. Molineaux
-
Susan M. Molineaux，2012年9月以来担任Geron董事。Calithera Biosciences是一家开发肿瘤治疗的私营生物技术公司，自从2010年6月联合建立这家公司以来，她担任公司的首席执行官兼总裁。在Calithera之前，Molineaux博士联合创立一家肿瘤为主导方向的生物制药公司Proteolix，并且2003年12月到2005年12月担任以及2009年2月到2009年11月担任首席科学官，2006年1月到2009年2月担任总裁兼首席执行官。Molineaux博士负责Proteolix第二代蛋白酶体抑制剂carfilzomib，现在市场上称为Kyprolis的开发，治疗多发性骨髓瘤，负责从发现到临床试验完成，加速获得批准，直到公司2009年11月被一家全球以肿瘤为主导方向的生物制药公司Onyx Pharmaceuticals收购。2000年到2003年，Molineaux博士担任一家专注炎症和自身免疫性疾病的生物制药公司Rigel Pharmaceuticals的生物副总裁。1999年到2000年以及1994年到1999年，她在一家肿瘤学为主导的生物制药公司Praecis Pharmaceuticals担任生物副总裁。1989年到1994年，她是一家制药公司默克的免疫学组的科学家。Molineaux博士拥有史密斯学院的生物学学士学位和约翰霍普金斯大学分子生物学的博士学位，也完成了哥伦比亚大学的博士后。她目前担任北加利福尼亚生命科学协会Bay Bio的主席，旧金山海岸数学科学研究项目We Teach Science董事会成员。
Susan M. Molineaux has served as a director of Geron since September 2012. Dr. Molineaux has been Chief Executive Officer, President and a member of the board of directors of Calithera Biosciences, Inc., a biotechnology company developing oncology therapeutics, since co-founding the company in June 2010. She also serves as a member of the board of directors of Theravance Biopharma, Inc., a biopharmaceutical company located in South San Francisco, since April 2015 where she is a member of the Sciences and Technology Committee, and as a Scientific Advisor to Lightstone Ventures, a private life sciences investment company, since September 2016. Prior to Calithera, Dr. Molineaux co-founded Proteolix, Inc., a privately-held oncology-oriented biopharmaceutical company, where she served as Chief Scientific Officer from December 2003 until December 2005 and from February 2009 until November 2009 and as President and Chief Executive Officer from January 2006 until February 2009 until the company’s acquisition by Onyx Pharmaceuticals, Inc., a global oncology-oriented biopharmaceutical company, in November 2009. Previously, Dr. Molineaux held several senior management positions in the biopharmaceutical industry, including Vice President of Biology at Rigel Pharmaceuticals, Inc., a biopharmaceutical company focused on inflammatory and autoimmune diseases; Vice President of Biology at Praelux, Inc., a biopharmaceutical company; and Vice President of Drug Development at Praecis Pharmaceuticals, Inc., an oncology-focused biopharmaceutical company. Dr. Molineaux holds a B.S. in biology from Smith College, a Ph.D. in molecular biology from Johns Hopkins University, and completed a postdoctoral fellowship at Columbia University. - Susan M. Molineaux，2012年9月以来担任Geron董事。Calithera Biosciences是一家开发肿瘤治疗的私营生物技术公司，自从2010年6月联合建立这家公司以来，她担任公司的首席执行官兼总裁。在Calithera之前，Molineaux博士联合创立一家肿瘤为主导方向的生物制药公司Proteolix，并且2003年12月到2005年12月担任以及2009年2月到2009年11月担任首席科学官，2006年1月到2009年2月担任总裁兼首席执行官。Molineaux博士负责Proteolix第二代蛋白酶体抑制剂carfilzomib，现在市场上称为Kyprolis的开发，治疗多发性骨髓瘤，负责从发现到临床试验完成，加速获得批准，直到公司2009年11月被一家全球以肿瘤为主导方向的生物制药公司Onyx Pharmaceuticals收购。2000年到2003年，Molineaux博士担任一家专注炎症和自身免疫性疾病的生物制药公司Rigel Pharmaceuticals的生物副总裁。1999年到2000年以及1994年到1999年，她在一家肿瘤学为主导的生物制药公司Praecis Pharmaceuticals担任生物副总裁。1989年到1994年，她是一家制药公司默克的免疫学组的科学家。Molineaux博士拥有史密斯学院的生物学学士学位和约翰霍普金斯大学分子生物学的博士学位，也完成了哥伦比亚大学的博士后。她目前担任北加利福尼亚生命科学协会Bay Bio的主席，旧金山海岸数学科学研究项目We Teach Science董事会成员。
- Susan M. Molineaux has served as a director of Geron since September 2012. Dr. Molineaux has been Chief Executive Officer, President and a member of the board of directors of Calithera Biosciences, Inc., a biotechnology company developing oncology therapeutics, since co-founding the company in June 2010. She also serves as a member of the board of directors of Theravance Biopharma, Inc., a biopharmaceutical company located in South San Francisco, since April 2015 where she is a member of the Sciences and Technology Committee, and as a Scientific Advisor to Lightstone Ventures, a private life sciences investment company, since September 2016. Prior to Calithera, Dr. Molineaux co-founded Proteolix, Inc., a privately-held oncology-oriented biopharmaceutical company, where she served as Chief Scientific Officer from December 2003 until December 2005 and from February 2009 until November 2009 and as President and Chief Executive Officer from January 2006 until February 2009 until the company’s acquisition by Onyx Pharmaceuticals, Inc., a global oncology-oriented biopharmaceutical company, in November 2009. Previously, Dr. Molineaux held several senior management positions in the biopharmaceutical industry, including Vice President of Biology at Rigel Pharmaceuticals, Inc., a biopharmaceutical company focused on inflammatory and autoimmune diseases; Vice President of Biology at Praelux, Inc., a biopharmaceutical company; and Vice President of Drug Development at Praecis Pharmaceuticals, Inc., an oncology-focused biopharmaceutical company. Dr. Molineaux holds a B.S. in biology from Smith College, a Ph.D. in molecular biology from Johns Hopkins University, and completed a postdoctoral fellowship at Columbia University.
高管简历
中英对照 | 中文 | 英文- John A. Scarlett
John A. Scarlett，2011年9月，担任我们首席执行官和董事，2012年1月以来担任总裁。在加入Geron之前，2009年2月以来，Scarlett博士是一家肿瘤学为主导方向的私营生物制药公司Proteolix的总裁，首席执行官和董事会成员，直到它2009年11月被一家肿瘤学为主导方向生物制药公司Onyx Pharmaceuticals收购。2002年2月以来，Scarlett博士担任一家内分泌学为主导方向的生物制药公司Tercica的首席执行官和董事会成员，之后它后来被Ipsen, S.A.收购，也从2002年2月到2007年2月担任它的总裁。1993年3月至2001年5月，Scarlett博士担任Sensus Drug Development Corporation的总裁兼首席执行官。1995年，他联合创立了一家合法生物制药制造公司Covance Biotechnology Services，并从它成立以来到2000年，担任它的董事会成员。1991年到1993年，Scarlett博士领导北美临产研究中心，担任一家Novo Nordisk A/S全资所有的子公司Novo Nordisk Pharmaceuticals的医疗科学事务官。Scarlett博士拥有厄勒姆学院化学专业学士学位和芝加哥大学普利兹克医学院的医学博士学位。
John A. Scarlett has served as Geron Corporation Chairman of the Board since December 2018 Geron Corporation Chief Executive Officer and a director since joining Geron in September 2011 and President since January 2012. Dr. Scarlett also serves as a member of the boards of directors for Chiasma, Inc., a biopharmaceutical company focused on transforming injectable drugs into oral medications, since February 2015 and CytomX Therapeutics, Inc., an oncology-oriented company, since June 2016. Prior to joining Geron, Dr. Scarlett served as President, Chief Executive Officer and a member of the board of directors of Proteolix, Inc., a privately-held, oncology-oriented biopharmaceutical company, from February 2009 until its acquisition by Onyx Pharmaceuticals, Inc., an oncology-oriented biopharmaceutical company, in November 2009. From February 2002 until its acquisition by Ipsen, S.A. in October 2008 Dr. Scarlett served as the Chief Executive Officer and a member of the board of directors of Tercica, Inc., an endocrinology-oriented biopharmaceutical company, and also as its President from February 2002 through February 2007. From March 1993 to May 2001 Dr. Scarlett served as President and Chief Executive Officer of Sensus Drug Development Corporation, a privately-held company focused on endocrine disorders. In 1995 he co-founded Covance Biotechnology Services, Inc., a contract biopharmaceutical manufacturing operation, and served as a member of its board of directors from inception to 2000. From 1991 to 1993 Dr. Scarlett headed the North American Clinical Development Center and served as Senior Vice President of Medical and Scientific Affairs at Novo Nordisk Pharmaceuticals, Inc., a wholly-owned subsidiary of Novo Nordisk A/S, a global pharmaceutical company. Dr. Scarlett received his B.A. degree in chemistry from Earlham College and his M.D. from the University of Chicago, Pritzker School of Medicine.- John A. Scarlett，2011年9月，担任我们首席执行官和董事，2012年1月以来担任总裁。在加入Geron之前，2009年2月以来，Scarlett博士是一家肿瘤学为主导方向的私营生物制药公司Proteolix的总裁，首席执行官和董事会成员，直到它2009年11月被一家肿瘤学为主导方向生物制药公司Onyx Pharmaceuticals收购。2002年2月以来，Scarlett博士担任一家内分泌学为主导方向的生物制药公司Tercica的首席执行官和董事会成员，之后它后来被Ipsen, S.A.收购，也从2002年2月到2007年2月担任它的总裁。1993年3月至2001年5月，Scarlett博士担任Sensus Drug Development Corporation的总裁兼首席执行官。1995年，他联合创立了一家合法生物制药制造公司Covance Biotechnology Services，并从它成立以来到2000年，担任它的董事会成员。1991年到1993年，Scarlett博士领导北美临产研究中心，担任一家Novo Nordisk A/S全资所有的子公司Novo Nordisk Pharmaceuticals的医疗科学事务官。Scarlett博士拥有厄勒姆学院化学专业学士学位和芝加哥大学普利兹克医学院的医学博士学位。
- John A. Scarlett has served as Geron Corporation Chairman of the Board since December 2018 Geron Corporation Chief Executive Officer and a director since joining Geron in September 2011 and President since January 2012. Dr. Scarlett also serves as a member of the boards of directors for Chiasma, Inc., a biopharmaceutical company focused on transforming injectable drugs into oral medications, since February 2015 and CytomX Therapeutics, Inc., an oncology-oriented company, since June 2016. Prior to joining Geron, Dr. Scarlett served as President, Chief Executive Officer and a member of the board of directors of Proteolix, Inc., a privately-held, oncology-oriented biopharmaceutical company, from February 2009 until its acquisition by Onyx Pharmaceuticals, Inc., an oncology-oriented biopharmaceutical company, in November 2009. From February 2002 until its acquisition by Ipsen, S.A. in October 2008 Dr. Scarlett served as the Chief Executive Officer and a member of the board of directors of Tercica, Inc., an endocrinology-oriented biopharmaceutical company, and also as its President from February 2002 through February 2007. From March 1993 to May 2001 Dr. Scarlett served as President and Chief Executive Officer of Sensus Drug Development Corporation, a privately-held company focused on endocrine disorders. In 1995 he co-founded Covance Biotechnology Services, Inc., a contract biopharmaceutical manufacturing operation, and served as a member of its board of directors from inception to 2000. From 1991 to 1993 Dr. Scarlett headed the North American Clinical Development Center and served as Senior Vice President of Medical and Scientific Affairs at Novo Nordisk Pharmaceuticals, Inc., a wholly-owned subsidiary of Novo Nordisk A/S, a global pharmaceutical company. Dr. Scarlett received his B.A. degree in chemistry from Earlham College and his M.D. from the University of Chicago, Pritzker School of Medicine.
- Anil Kapur
Anil Kapur自2019年12月起担任Geron Corporation公司战略执行副总裁和首席商务官。加入Geron之前，他是Actinium Pharmaceuticals, Inc.(临床阶段生物制药公司)的首席商务官(从2018年2月到2019年11月)。从2016年10月到2018年2月，他担任Bristol-Myers Squibb Company(一家全球生物制药公司)的副总裁，负责全球肿瘤商业化的早期资产、生物标记和外部创新。他曾担任Baxalta, Incorporated(一家生物制药公司)的副总裁、商业和投资组合战略全球主管(从2015年11月到2016年7月被Shire plc收购)。在加入Baxalta之前，他在Johnson & Johnson Janssen制药公司(Janssen Pharmaceutical Companies of Johnson & Johnson Janssen)任职15年，担任营销和销售领导职务。作为Janssen的全球商业战略组织的血液学加盟商业副总裁，他领导了市场开发、后期开发和早期管道资产的商业战略和启动计划的开发和执行，包括imetelstat。在Janssen任职期间，Kapur先生最受认可的成就之一是成功地在全球推出了两款变革性的畅销血液肿瘤学药物Imbruvica和Darzalex。他持有印度Birla Institute of Technology的工程学士学位;路易斯安那理工大学工业工程硕士学位;杜克大学福库商学院(Fuqua School of Business at Duke University)工商管理硕士学位。
Anil Kapur has served as Geron Corporation Executive Vice President, Corporate Strategy and Chief Commercial Officer since December 2019. Prior to joining Geron, Mr. Kapur was Chief Commercial Officer at Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, from February 2018 to November 2019. From October 2016 until February 2018 Mr. Kapur was Vice President, Head of Early Assets, Biomarkers and External Innovation for Worldwide Oncology Commercialization at Bristol-Myers Squibb Company, a global biopharmaceutical company. Mr. Kapur served as Vice President, Global Head of Commercial and Portfolio Strategy at Baxalta, Incorporated, a biopharmaceutical company, in a newly created Oncology Division, from November 2015 until after its acquisition by Shire plc in July 2016. Before joining Baxalta, Mr. Kapur held marketing and sales leadership roles of increasing responsibility during his 15-year tenure at the Janssen Pharmaceutical Companies of Johnson & Johnson Janssen. As Vice President, Commercial Leader, Hematology Franchise in Janssen's Global Commercial Strategy Organization, he led the development and execution of commercial strategy and launch plans for in-market development, late development, and early pipeline assets, including imetelstat. Among Mr. Kapur's most recognized achievements while at Janssen were the successful global launches of two transformational blockbuster hematology-oncology drugs, Imbruvica and Darzalex. Mr. Kapur holds a Bachelor of Engineering from Birla Institute of Technology in India; an M.S. in Industrial Engineering from Louisiana Tech University; and an M.B.A. from the Fuqua School of Business at Duke University.- Anil Kapur自2019年12月起担任Geron Corporation公司战略执行副总裁和首席商务官。加入Geron之前，他是Actinium Pharmaceuticals, Inc.(临床阶段生物制药公司)的首席商务官(从2018年2月到2019年11月)。从2016年10月到2018年2月，他担任Bristol-Myers Squibb Company(一家全球生物制药公司)的副总裁，负责全球肿瘤商业化的早期资产、生物标记和外部创新。他曾担任Baxalta, Incorporated(一家生物制药公司)的副总裁、商业和投资组合战略全球主管(从2015年11月到2016年7月被Shire plc收购)。在加入Baxalta之前，他在Johnson & Johnson Janssen制药公司(Janssen Pharmaceutical Companies of Johnson & Johnson Janssen)任职15年，担任营销和销售领导职务。作为Janssen的全球商业战略组织的血液学加盟商业副总裁，他领导了市场开发、后期开发和早期管道资产的商业战略和启动计划的开发和执行，包括imetelstat。在Janssen任职期间，Kapur先生最受认可的成就之一是成功地在全球推出了两款变革性的畅销血液肿瘤学药物Imbruvica和Darzalex。他持有印度Birla Institute of Technology的工程学士学位;路易斯安那理工大学工业工程硕士学位;杜克大学福库商学院(Fuqua School of Business at Duke University)工商管理硕士学位。
- Anil Kapur has served as Geron Corporation Executive Vice President, Corporate Strategy and Chief Commercial Officer since December 2019. Prior to joining Geron, Mr. Kapur was Chief Commercial Officer at Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, from February 2018 to November 2019. From October 2016 until February 2018 Mr. Kapur was Vice President, Head of Early Assets, Biomarkers and External Innovation for Worldwide Oncology Commercialization at Bristol-Myers Squibb Company, a global biopharmaceutical company. Mr. Kapur served as Vice President, Global Head of Commercial and Portfolio Strategy at Baxalta, Incorporated, a biopharmaceutical company, in a newly created Oncology Division, from November 2015 until after its acquisition by Shire plc in July 2016. Before joining Baxalta, Mr. Kapur held marketing and sales leadership roles of increasing responsibility during his 15-year tenure at the Janssen Pharmaceutical Companies of Johnson & Johnson Janssen. As Vice President, Commercial Leader, Hematology Franchise in Janssen's Global Commercial Strategy Organization, he led the development and execution of commercial strategy and launch plans for in-market development, late development, and early pipeline assets, including imetelstat. Among Mr. Kapur's most recognized achievements while at Janssen were the successful global launches of two transformational blockbuster hematology-oncology drugs, Imbruvica and Darzalex. Mr. Kapur holds a Bachelor of Engineering from Birla Institute of Technology in India; an M.S. in Industrial Engineering from Louisiana Tech University; and an M.B.A. from the Fuqua School of Business at Duke University.
- Aleksandra Rizo
Aleksandra Rizo，医学博士，博士，自2019年1月起担任Geron Corporation的执行副总裁、首席医疗官。加入Geron之前，Rizo博士于2018年3月至2019年1月担任Celgene Corporation（一家生物制药公司）的执行董事，战略和临床主管，在那里她领导提交活动，并参与战略和业务发展倡议。从2008年10月到2018年3月，Rizo博士在Janssen Research and development, LLC（一家制药公司）担任多个肿瘤药物开发职能，包括高级总监，所有1期髓系资产的化合物开发团队负责人，以及所有晚期髓系资产的全球临床负责人。包括2014年11月至2018年3月的imetelstat，以及ibrutinib套细胞淋巴瘤项目的全球临床领导者。在这些角色中，她负责监督和领导整体临床开发策略、研究设计、执行和数据解释。此外，Rizo博士是Janssen的血液学战略团队的核心成员，在那里她参与并领导了血液学的勤勉项目。在Janssen的最初任期内，Rizo博士还在淋巴瘤和多发性骨髓瘤的Velcade临床试验中工作。Rizo博士持有the University Ss Cyril and Methodius, Skopje, Macedonia，她还完成了内科/血液学住院医师学位。她还获得了荷兰格罗宁根大学（University of Groningen）的人类白血病干细胞生物学博士学位，以及日本东京大学（University of Tokyo）的小鼠干细胞生物学博士学位。
Aleksandra Rizo, M.D., Ph.D., has served as Geron Corporation Executive Vice President, Chief Medical Officer since January 2019. Prior to joining Geron, Dr. Rizo was Executive Director, Strategy and Clinical Lead at Celgene Corporation, a biopharmaceutical company, from March 2018 to January 2019 where she led submission activities and participated in strategic and business development initiatives. From October 2008 to March 2018 Dr. Rizo served in a number of oncology drug development functions at Janssen Research and Development, LLC, a pharmaceutical company, including Senior Director, Compound Development Team Leader for all Phase 1 myeloid assets, and Global Clinical Leader for all late-stage myeloid assets, including imetelstat from November 2014 to March 2018 as well as Global Clinical Leader for the ibrutinib mantle cell lymphoma program. In these roles, she had oversight and leadership responsibilities for overall clinical development strategy, study designs, execution and data interpretation. In addition, Dr. Rizo was a core member of Janssen's Hematology Strategy Team where she participated and led diligence projects in hematology. During her initial tenure with Janssen, Dr. Rizo also worked on a variety of Velcade clinical trials in lymphoma and multiple myeloma. Dr. Rizo holds an M.D. from the University Ss Cyril and Methodius, Skopje, Macedonia, where she also completed a residency in internal medicine/hematology. She also has a Ph.D. in human leukemic stem cell biology from the University of Groningen, Groningen, Netherlands, and a Ph.D. in mouse stem cell biology from the University of Tokyo, Tokyo, Japan.- Aleksandra Rizo，医学博士，博士，自2019年1月起担任Geron Corporation的执行副总裁、首席医疗官。加入Geron之前，Rizo博士于2018年3月至2019年1月担任Celgene Corporation（一家生物制药公司）的执行董事，战略和临床主管，在那里她领导提交活动，并参与战略和业务发展倡议。从2008年10月到2018年3月，Rizo博士在Janssen Research and development, LLC（一家制药公司）担任多个肿瘤药物开发职能，包括高级总监，所有1期髓系资产的化合物开发团队负责人，以及所有晚期髓系资产的全球临床负责人。包括2014年11月至2018年3月的imetelstat，以及ibrutinib套细胞淋巴瘤项目的全球临床领导者。在这些角色中，她负责监督和领导整体临床开发策略、研究设计、执行和数据解释。此外，Rizo博士是Janssen的血液学战略团队的核心成员，在那里她参与并领导了血液学的勤勉项目。在Janssen的最初任期内，Rizo博士还在淋巴瘤和多发性骨髓瘤的Velcade临床试验中工作。Rizo博士持有the University Ss Cyril and Methodius, Skopje, Macedonia，她还完成了内科/血液学住院医师学位。她还获得了荷兰格罗宁根大学（University of Groningen）的人类白血病干细胞生物学博士学位，以及日本东京大学（University of Tokyo）的小鼠干细胞生物学博士学位。
- Aleksandra Rizo, M.D., Ph.D., has served as Geron Corporation Executive Vice President, Chief Medical Officer since January 2019. Prior to joining Geron, Dr. Rizo was Executive Director, Strategy and Clinical Lead at Celgene Corporation, a biopharmaceutical company, from March 2018 to January 2019 where she led submission activities and participated in strategic and business development initiatives. From October 2008 to March 2018 Dr. Rizo served in a number of oncology drug development functions at Janssen Research and Development, LLC, a pharmaceutical company, including Senior Director, Compound Development Team Leader for all Phase 1 myeloid assets, and Global Clinical Leader for all late-stage myeloid assets, including imetelstat from November 2014 to March 2018 as well as Global Clinical Leader for the ibrutinib mantle cell lymphoma program. In these roles, she had oversight and leadership responsibilities for overall clinical development strategy, study designs, execution and data interpretation. In addition, Dr. Rizo was a core member of Janssen's Hematology Strategy Team where she participated and led diligence projects in hematology. During her initial tenure with Janssen, Dr. Rizo also worked on a variety of Velcade clinical trials in lymphoma and multiple myeloma. Dr. Rizo holds an M.D. from the University Ss Cyril and Methodius, Skopje, Macedonia, where she also completed a residency in internal medicine/hematology. She also has a Ph.D. in human leukemic stem cell biology from the University of Groningen, Groningen, Netherlands, and a Ph.D. in mouse stem cell biology from the University of Tokyo, Tokyo, Japan.
- Melissa A. Kelly Behrs
Melissa A. Kelly Behrs，2012年9月以来担任Geron Corporation的投资组合和联盟管理的高级副总裁，之前2011年5月以来担任Geron Corporation的战略组合投资管理和产品开发制造的高级副总裁。2007年1月到2011年5月，她担任医疗开发和肿瘤学高级副总裁。2002年4月到2003年1月，Behrs女士担任Geron Corporation的企业开发副总裁。2001年4月到2002年4月，Behrs女士担任Geron Corporation的项目和开发技术总经理。Behrs女士1998年11月加入Geron Corporation，担任企业开发董事。1990年到1998年，Behrs女士在一家生物技术项目和开发公司Genetics工作，期初担任助理财务总监，之后担任临床运营副董事，负责临床运营方面的所有商业开发、监管和项目管理活动。Behrs女士拥有波士顿学院的学士学位和巴布森学院的MBA学位。
Melissa A. Kelly Behrs has served as Geron Corporation Executive Vice President, Chief Business Officer since January 2019. Previously, she was Geron Corporation Executive Vice President, Business Development and Portfolio & Alliance Management, from February 2014 to January 2019 and our Senior Vice President, Portfolio and Alliance Management from September 2012 to February 2014. Ms. Behrs joined Geron in November 1998 as Director of Corporate Development. Since then, she has also served in various managerial positions, including General Manager, R&D Technologies; Vice President, Corporate Development; Senior Vice President, Therapeutic Development, Oncology; and Senior Vice President, Strategic Portfolio Management. From 1990 to 1998 Ms. Behrs worked at Genetics Institute, Inc., a biotechnology research and development company, serving initially as Assistant Treasurer and then as Associate Director of Preclinical Operations where she was responsible for all business development, regulatory, and project management activities for the Preclinical Development function. Ms. Behrs received a B.S. from Boston College and an M.B.A. from Babson College.- Melissa A. Kelly Behrs，2012年9月以来担任Geron Corporation的投资组合和联盟管理的高级副总裁，之前2011年5月以来担任Geron Corporation的战略组合投资管理和产品开发制造的高级副总裁。2007年1月到2011年5月，她担任医疗开发和肿瘤学高级副总裁。2002年4月到2003年1月，Behrs女士担任Geron Corporation的企业开发副总裁。2001年4月到2002年4月，Behrs女士担任Geron Corporation的项目和开发技术总经理。Behrs女士1998年11月加入Geron Corporation，担任企业开发董事。1990年到1998年，Behrs女士在一家生物技术项目和开发公司Genetics工作，期初担任助理财务总监，之后担任临床运营副董事，负责临床运营方面的所有商业开发、监管和项目管理活动。Behrs女士拥有波士顿学院的学士学位和巴布森学院的MBA学位。
- Melissa A. Kelly Behrs has served as Geron Corporation Executive Vice President, Chief Business Officer since January 2019. Previously, she was Geron Corporation Executive Vice President, Business Development and Portfolio & Alliance Management, from February 2014 to January 2019 and our Senior Vice President, Portfolio and Alliance Management from September 2012 to February 2014. Ms. Behrs joined Geron in November 1998 as Director of Corporate Development. Since then, she has also served in various managerial positions, including General Manager, R&D Technologies; Vice President, Corporate Development; Senior Vice President, Therapeutic Development, Oncology; and Senior Vice President, Strategic Portfolio Management. From 1990 to 1998 Ms. Behrs worked at Genetics Institute, Inc., a biotechnology research and development company, serving initially as Assistant Treasurer and then as Associate Director of Preclinical Operations where she was responsible for all business development, regulatory, and project management activities for the Preclinical Development function. Ms. Behrs received a B.S. from Boston College and an M.B.A. from Babson College.
- Stephen N. Rosenfield
Stephen N. Rosenfield，法学博士，2012年2月以来担任Geron Corporation执行副总裁，法律总顾问，公司秘书长，2012年1月以来担任法律总顾问和秘书长，2011年10月以来担任秘书长。2009年7月到2012年2月，Rosenfield先生担任私营公司的顾问。2008年10月至2009年6月，Rosenfield先生是一家全球专业制药公司Ipsen, SA旗下子公司Tercica的法律总顾问兼秘书长。2004年6月到2008年10月，Rosenfield先生是Tercica，一家内分泌学主导的生物制药公司的法律总顾问兼秘书长，2006年1月到2008年10月，他也是Legal Affairs的执行副总裁。Rosenfield先生拥有霍夫斯特拉大学的学士学位和东北大学法学院法学博士。
Stephen N. Rosenfield, J.D., has served as Geron Corporation Executive Vice President, Chief Legal Officer and Corporate Secretary since January 2019. Previously, he served as our Executive Vice President, General Counsel and Corporate Secretary from February 2012 to January 2019 General Counsel and Secretary since January 2012 and Secretary since October 2011. Mr. Rosenfield received a B.S. from Hofstra University and a J.D. from Northeastern University School of Law.- Stephen N. Rosenfield，法学博士，2012年2月以来担任Geron Corporation执行副总裁，法律总顾问，公司秘书长，2012年1月以来担任法律总顾问和秘书长，2011年10月以来担任秘书长。2009年7月到2012年2月，Rosenfield先生担任私营公司的顾问。2008年10月至2009年6月，Rosenfield先生是一家全球专业制药公司Ipsen, SA旗下子公司Tercica的法律总顾问兼秘书长。2004年6月到2008年10月，Rosenfield先生是Tercica，一家内分泌学主导的生物制药公司的法律总顾问兼秘书长，2006年1月到2008年10月，他也是Legal Affairs的执行副总裁。Rosenfield先生拥有霍夫斯特拉大学的学士学位和东北大学法学院法学博士。
- Stephen N. Rosenfield, J.D., has served as Geron Corporation Executive Vice President, Chief Legal Officer and Corporate Secretary since January 2019. Previously, he served as our Executive Vice President, General Counsel and Corporate Secretary from February 2012 to January 2019 General Counsel and Secretary since January 2012 and Secretary since October 2011. Mr. Rosenfield received a B.S. from Hofstra University and a J.D. from Northeastern University School of Law.
- Olivia K. Bloom
Olivia K. Bloom，2012年12月以来担任Geron Corporation高级副总裁兼首席财务官，2011年2月以来担任财务总监。2010年9月到2012年12月，Bloom女士担任Geron Corporation首席财务官以及2007年1月至2012年12月担任副总裁。Bloom女士1994年加入到公司，担任高级财务分析师，1996年到2011年，担任我们总会计师。在Geron之前，Bloom女士在毕马威会计事务所开始了她的职业生涯，并在1994年成为一名注册会计师。Bloom女士是美国大学优等生荣誉学会成员，拥有加州大学伯克利分校工商管理学士学位。
Olivia K. Bloom has served as Geron Corporation Executive Vice President, Finance since February 2014 Chief Financial Officer since December 2012 and Treasurer since February 2011. Ms. Bloom previously served as our Senior Vice President, Finance from December 2012 to February 2014 Chief Accounting Officer from September 2010 to December 2012 and Vice President, Finance from January 2007 to December 2012. Ms. Bloom joined the Company in 1994 as a Senior Financial Analyst and from 1996 to 2011 served as our Controller. Prior to joining Geron, Ms. Bloom started her career in public accounting at KPMG Peat Marwick and became a Certified Public Accountant in 1994. Ms. Bloom graduated Phi Beta Kappa with a B.S. in Business Administration from the University of California at Berkeley.- Olivia K. Bloom，2012年12月以来担任Geron Corporation高级副总裁兼首席财务官，2011年2月以来担任财务总监。2010年9月到2012年12月，Bloom女士担任Geron Corporation首席财务官以及2007年1月至2012年12月担任副总裁。Bloom女士1994年加入到公司，担任高级财务分析师，1996年到2011年，担任我们总会计师。在Geron之前，Bloom女士在毕马威会计事务所开始了她的职业生涯，并在1994年成为一名注册会计师。Bloom女士是美国大学优等生荣誉学会成员，拥有加州大学伯克利分校工商管理学士学位。
- Olivia K. Bloom has served as Geron Corporation Executive Vice President, Finance since February 2014 Chief Financial Officer since December 2012 and Treasurer since February 2011. Ms. Bloom previously served as our Senior Vice President, Finance from December 2012 to February 2014 Chief Accounting Officer from September 2010 to December 2012 and Vice President, Finance from January 2007 to December 2012. Ms. Bloom joined the Company in 1994 as a Senior Financial Analyst and from 1996 to 2011 served as our Controller. Prior to joining Geron, Ms. Bloom started her career in public accounting at KPMG Peat Marwick and became a Certified Public Accountant in 1994. Ms. Bloom graduated Phi Beta Kappa with a B.S. in Business Administration from the University of California at Berkeley.
- Andrew J. Grethlein
Andrew J. Grethlein，博士，2012年9月以来担任我们的执行副总裁，负责技术运营。在加入Geron之前，2010年1月到2012年9月，Grethlein博士是一家生物制药公司Inspiration Biopharmaceuticals的执行副总裁兼首席运营官。2008年10月到2010年1月，Grethlein博士是一家全球专业制药公司Ipsen S.A.血液学生物技术与投资组合管理领导团队的高级副总裁。他在Ipsen的责任包括产品全球战略规划和执行，以及血液学治疗领域的投资组合管理。2003年到2008年，Grethlein博士担任一家内分泌学为主导方向的生物制药公司Tercica的制药运营高级副总裁。在这个职位上，他是管理公司战略、商业规划和公司运营高级执行团队的成员，负责所有制造和质量方面的工作。在加入Tercica之前，1997年到2003年，Grethlein博士在一家生物技术公司Elan Corporation担任了各种职位，包括高级董事，南旧金山地区的制药运营官，在那里，他担任商业制造运营地区负责人。1995年到2003年，Grethlein博士担任一家制药公司Athena Neurosciences的经理，负责生物制剂开发和制造。在这之前，他在一个非盈利技术项目和商业开发公司the Michigan Biotechnology Institute的各种工程职位。Grethlein博士拥有Simon's Rock早期学院的准学士学位，贝茨学院的学士学位，密歇根州立大学化学工程专业的硕士学位和博士学位。
Andrew J. Grethlein, Ph.D.,has served as Geron Corporation Executive Vice President, Chief Operating Officer since January 2019. Previously, he served as Geron Corporation Executive Vice President, Development and Technical Operations, from July 2014 to January 2019. He joined Geron in September 2012 as Geron Corporation Executive Vice President, Technical Operations. Prior to joining Geron, Dr. Grethlein was Executive Vice President and Chief Operating Officer for Inspiration Biopharmaceuticals, a biopharmaceutical company, from January 2010 to September 2012. From October 2008 until January 2010 Dr. Grethlein was Senior Vice President of Biotechnology and Portfolio Management Team Leader for Hematology at Ipsen S.A., a global specialty pharmaceutical company. His responsibilities at Ipsen included planning and execution of worldwide strategy for product and portfolio development in the hematologic therapeutic area. From 2003 to 2008 Dr. Grethlein served as Senior Vice President of Pharmaceutical Operations at Tercica, Inc., an endocrinology-oriented biopharmaceutical company, where he was a member of the senior executive team that governed corporate strategy, business planning and company operations, and had responsibility for all manufacturing and quality functions. Before joining Tercica, Dr. Grethlein served in various positions at Elan Corporation, a biotechnology company, from 1997 to 2003 including as Senior Director, South San Francisco Pharmaceutical Operations. From 1995 to 1997 Dr. Grethlein served as Manager, Biologics Development and Manufacturing, for Athena Neurosciences, Inc., a pharmaceutical company. Prior to this, he served in various engineering positions for the Michigan Biotechnology Institute, a nonprofit technology research and business development corporation. Dr. Grethlein received his A.A. degree in liberal arts from Simon's Rock Early College, his B.S. in biology from Bates College, and his M.S. and Ph.D. in chemical engineering from Michigan State University.- Andrew J. Grethlein，博士，2012年9月以来担任我们的执行副总裁，负责技术运营。在加入Geron之前，2010年1月到2012年9月，Grethlein博士是一家生物制药公司Inspiration Biopharmaceuticals的执行副总裁兼首席运营官。2008年10月到2010年1月，Grethlein博士是一家全球专业制药公司Ipsen S.A.血液学生物技术与投资组合管理领导团队的高级副总裁。他在Ipsen的责任包括产品全球战略规划和执行，以及血液学治疗领域的投资组合管理。2003年到2008年，Grethlein博士担任一家内分泌学为主导方向的生物制药公司Tercica的制药运营高级副总裁。在这个职位上，他是管理公司战略、商业规划和公司运营高级执行团队的成员，负责所有制造和质量方面的工作。在加入Tercica之前，1997年到2003年，Grethlein博士在一家生物技术公司Elan Corporation担任了各种职位，包括高级董事，南旧金山地区的制药运营官，在那里，他担任商业制造运营地区负责人。1995年到2003年，Grethlein博士担任一家制药公司Athena Neurosciences的经理，负责生物制剂开发和制造。在这之前，他在一个非盈利技术项目和商业开发公司the Michigan Biotechnology Institute的各种工程职位。Grethlein博士拥有Simon's Rock早期学院的准学士学位，贝茨学院的学士学位，密歇根州立大学化学工程专业的硕士学位和博士学位。
- Andrew J. Grethlein, Ph.D.,has served as Geron Corporation Executive Vice President, Chief Operating Officer since January 2019. Previously, he served as Geron Corporation Executive Vice President, Development and Technical Operations, from July 2014 to January 2019. He joined Geron in September 2012 as Geron Corporation Executive Vice President, Technical Operations. Prior to joining Geron, Dr. Grethlein was Executive Vice President and Chief Operating Officer for Inspiration Biopharmaceuticals, a biopharmaceutical company, from January 2010 to September 2012. From October 2008 until January 2010 Dr. Grethlein was Senior Vice President of Biotechnology and Portfolio Management Team Leader for Hematology at Ipsen S.A., a global specialty pharmaceutical company. His responsibilities at Ipsen included planning and execution of worldwide strategy for product and portfolio development in the hematologic therapeutic area. From 2003 to 2008 Dr. Grethlein served as Senior Vice President of Pharmaceutical Operations at Tercica, Inc., an endocrinology-oriented biopharmaceutical company, where he was a member of the senior executive team that governed corporate strategy, business planning and company operations, and had responsibility for all manufacturing and quality functions. Before joining Tercica, Dr. Grethlein served in various positions at Elan Corporation, a biotechnology company, from 1997 to 2003 including as Senior Director, South San Francisco Pharmaceutical Operations. From 1995 to 1997 Dr. Grethlein served as Manager, Biologics Development and Manufacturing, for Athena Neurosciences, Inc., a pharmaceutical company. Prior to this, he served in various engineering positions for the Michigan Biotechnology Institute, a nonprofit technology research and business development corporation. Dr. Grethlein received his A.A. degree in liberal arts from Simon's Rock Early College, his B.S. in biology from Bates College, and his M.S. and Ph.D. in chemical engineering from Michigan State University.